129 related articles for article (PubMed ID: 30059794)
1. In session extinction and outcome in Virtual Reality Exposure Therapy for PTSD.
Rauch SAM; Koola C; Post L; Yasinski C; Norrholm SD; Black K; Rothbaum BO
Behav Res Ther; 2018 Oct; 109():1-9. PubMed ID: 30059794
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.
Rothbaum BO; Price M; Jovanovic T; Norrholm SD; Gerardi M; Dunlop B; Davis M; Bradley B; Duncan EJ; Rizzo A; Ressler KJ
Am J Psychiatry; 2014 Jun; 171(6):640-8. PubMed ID: 24743802
[TBL] [Abstract][Full Text] [Related]
3. Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy.
Norrholm SD; Jovanovic T; Gerardi M; Breazeale KG; Price M; Davis M; Duncan E; Ressler KJ; Bradley B; Rizzo A; Tuerk PW; Rothbaum BO
Behav Res Ther; 2016 Jul; 82():28-37. PubMed ID: 27183343
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic augmentation of extinction learning during exposure therapy for PTSD.
Neylan TC
Am J Psychiatry; 2014 Jun; 171(6):597-9. PubMed ID: 24880503
[No Abstract] [Full Text] [Related]
5. The impact of benzodiazepine management in the randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy.
Granoff AL
Am J Psychiatry; 2014 Nov; 171(11):1222. PubMed ID: 25756634
[No Abstract] [Full Text] [Related]
6. D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.
Difede J; Cukor J; Wyka K; Olden M; Hoffman H; Lee FS; Altemus M
Neuropsychopharmacology; 2014 Apr; 39(5):1052-8. PubMed ID: 24217129
[TBL] [Abstract][Full Text] [Related]
7. Possible negative effects of extinction learning on outcomes for patients receiving exposure therapy.
Smith E
Am J Psychiatry; 2014 Nov; 171(11):1222-3. PubMed ID: 25756636
[No Abstract] [Full Text] [Related]
8. Extinction learning as a moderator of d-cycloserine efficacy for enhancing exposure therapy in posttraumatic stress disorder.
de Kleine RA; Smits JA; Hendriks GJ; Becker ES; van Minnen A
J Anxiety Disord; 2015 Aug; 34():63-7. PubMed ID: 26121495
[TBL] [Abstract][Full Text] [Related]
9. Between-session and within-session habituation in Prolonged Exposure Therapy for posttraumatic stress disorder: a hierarchical linear modeling approach.
Sripada RK; Rauch SA
J Anxiety Disord; 2015 Mar; 30():81-7. PubMed ID: 25613235
[TBL] [Abstract][Full Text] [Related]
10. The relationship between posttraumatic and depressive symptoms during virtual reality exposure therapy with a cognitive enhancer.
Peskin M; Wyka K; Cukor J; Olden M; Altemus M; Lee FS; Difede J
J Anxiety Disord; 2019 Jan; 61():82-88. PubMed ID: 29580634
[TBL] [Abstract][Full Text] [Related]
11. Does virtual reality increase emotional engagement during exposure for PTSD? Subjective distress during prolonged and virtual reality exposure therapy.
Reger GM; Smolenski D; Norr A; Katz A; Buck B; Rothbaum BO
J Anxiety Disord; 2019 Jan; 61():75-81. PubMed ID: 29935999
[TBL] [Abstract][Full Text] [Related]
12. Response to Smith.
Rothbaum BO; Price M; Ressler K
Am J Psychiatry; 2014 Nov; 171(11):1223-4. PubMed ID: 25756637
[No Abstract] [Full Text] [Related]
13. Response to Granoff.
Rothbaum BO; Ressler K
Am J Psychiatry; 2014 Nov; 171(11):1222. PubMed ID: 25756635
[No Abstract] [Full Text] [Related]
14. An investigation of outcome expectancies as a predictor of treatment response for combat veterans with PTSD: comparison of clinician, self-report, and biological measures.
Price M; Maples JL; Jovanovic T; Norrholm SD; Heekin M; Rothbaum BO
Depress Anxiety; 2015 Jun; 32(6):392-9. PubMed ID: 25703611
[TBL] [Abstract][Full Text] [Related]
15. Enhanced exposure therapy for combat-related Posttraumatic Stress Disorder (PTSD): Study protocol for a randomized controlled trial.
Difede J; Rothbaum BO; Rizzo AA; Wyka K; Spielman L; Jovanovic T; Reist C; Roy MJ; Norrholm SD; Glatt C; Lee F
Contemp Clin Trials; 2019 Dec; 87():105857. PubMed ID: 31669451
[TBL] [Abstract][Full Text] [Related]
16. Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress.
Scheeringa MS; Weems CF
J Child Adolesc Psychopharmacol; 2014 Mar; 24(2):69-77. PubMed ID: 24506079
[TBL] [Abstract][Full Text] [Related]
17. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.
Ressler KJ; Rothbaum BO; Tannenbaum L; Anderson P; Graap K; Zimand E; Hodges L; Davis M
Arch Gen Psychiatry; 2004 Nov; 61(11):1136-44. PubMed ID: 15520361
[TBL] [Abstract][Full Text] [Related]
18. When translational neuroscience fails in the clinic: Dexamethasone prior to virtual reality exposure therapy increases drop-out rates.
Maples-Keller JL; Jovanovic T; Dunlop BW; Rauch S; Yasinski C; Michopoulos V; Coghlan C; Norrholm S; Rizzo AS; Ressler K; Rothbaum BO
J Anxiety Disord; 2019 Jan; 61():89-97. PubMed ID: 30502903
[TBL] [Abstract][Full Text] [Related]
19. Augmenting treatment efficiency in exposure therapy for PTSD: a randomized double-blind placebo-controlled trial of yohimbine HCl.
Tuerk PW; Wangelin BC; Powers MB; Smits JAJ; Acierno R; Myers US; Orr SP; Foa EB; Hamner MB
Cogn Behav Ther; 2018 Sep; 47(5):351-371. PubMed ID: 29448886
[TBL] [Abstract][Full Text] [Related]
20. You can do that?!: Feasibility of virtual reality exposure therapy in the treatment of PTSD due to military sexual trauma.
Loucks L; Yasinski C; Norrholm SD; Maples-Keller J; Post L; Zwiebach L; Fiorillo D; Goodlin M; Jovanovic T; Rizzo AA; Rothbaum BO
J Anxiety Disord; 2019 Jan; 61():55-63. PubMed ID: 30005843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
